Entera Bio Ltd.
ENTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -76.5% | – |
| Gross Profit | $0 | -$0 | -$0 | $0 |
| % Margin | 5% | – | -23.1% | 34.7% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -5,270.2% | – | -9,604.5% | -2,130.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -5,271.3% | – | -9,754.5% | -2,134.3% |
| EPS Diluted | -0.25 | -0.31 | -0.45 | -0.47 |
| % Growth | 19.4% | 31.1% | 4.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |